OMTX 705
OMTX 705 (OMTX005+TAM470) is an antibody-drug conjugate (ADC) targeting FAP, with an EC50 of 76 pM. OMTX 705 selectively induces apoptosis in FAP-expressing tumor cells through caspase 3/7 activation. OMTX 705 inhibits tumor growth and induces regression in multiple tumor models. OMTX 705 can be used for research on solid tumors, including pancreatic cancer, non-small cell lung cancer, triple-negative breast cancer, and ovarian cancer.
For research use only. We do not sell to patients.
- CAS No.: 3028851-79-5
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
FAP 76 pM (EC50) |
Caspase 3 |
Caspase-7 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HT1080-WT, HT1080-FAP, and CAF07 cells
-
Concentration:400 nM (starting; 1:4 serial dilutions)
-
Incubation Time:5 days
-
Result:Showed FAP-specific cytotoxic activity with an IC50 of approximately 230 pM in HT1080-FAP cells and a 500-fold specificity ratio versus HT1080-WT cells; in primary CAF07 cells, the IC50 was approximately 400 nM.
In Vivo
OMTX 705 (10-30 mg/kg; i.v.; once weekly; four doses total) inhibits tumor growth in the Breast 014 TNBC PDX model[1].
OMTX 705 (30 mg/kg; i.v.; once weekly) inhibits tumor growth in the Ovary 020 ovarian cancer PDX model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Foxn1 nu/nu (nude; female; 5 weeks old)[1]
-
Dosage:20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg
-
Administration:i.v.; i.p.; once weekly; twice in the first week; four doses; interrupted on day 16 and restarted on day 29; continued to day 30
-
Result:At i.v. doses above 30 mg/kg once weekly, tumor regressions lasted at least 5 weeks.
Single-agent activity was observed at 20 mg/kg i.p.
At 10 mg/kg combined with Gemcitabine, durable tumor regressions lasted at least 90 days.
In the cyclic schedule, G1 and G4 were interrupted on day 16 and restarted on day 29; tumor responses were again observed at day 36 and onward, suggesting lack of resistance.
At 30 mg/kg weekly, TGI was above 80% at day 28, and Panc007 was the most sensitive PDX model.
At 30 mg/kg weekly i.v., binding was predominantly to fusiform intratumoral stromal cells with no staining in malignant epithelial cells; payload was detected in stromal cells from day 3 and in tumor cells from day 10; Ki-67+ tumor cells decreased at day 24; active caspase-3 increased in malignant epithelial cells from day 3 to day 24; aSMA decreased by 70% and COL11A1 by 80% at day 47 (n = 10).
-
Animal Model:Foxn1 nu/nu (nude; female; 5 weeks old)[1]
-
Dosage:10 mg/kg, 30 mg/kg
-
Administration:i.p.; i.v.; once weekly; twice in the first week; from the second week
-
Result:At 10 mg/kg i.p., tumor growth inhibition occurred, while 30 mg/kg i.p. showed higher efficacy with no apparent toxicity.
Paclitaxel monotherapy was less effective, and synergistic effects were observed with Paclitaxel combination.
In the summary TGI analysis, at 30 mg/kg weekly, TGI was above 80% at day 28 in Lung 024.
-
Animal Model:Foxn1 nu/nu (nude; female; 5 weeks old)[1]
-
Dosage:10 mg/kg, 30 mg/kg
-
Administration:i.v.; once weekly; four doses; from the second week
-
Result:At 30 mg/kg i.v., efficacy was best, while 10 mg/kg i.v. with or without paclitaxel had more limited effects.
At 30 mg/kg weekly i.v., TGI was above 80% at day 28.
-
Animal Model:Foxn1 nu/nu (nude; female; 5 weeks old)[1]
-
Dosage:30 mg/kg i.v. once weekly
-
Administration:i.v.; once weekly
-
Result:At 30 mg/kg weekly i.v., TGI was above 80% at day 30.
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Annexin V plus membrane-impermeant dye apoptosis staining
- Patient-Derived Xenograft (PDX)
- Apoptosis Solutions
- Patient-Derived Orthotopic Xenograft (PDOX)
- Subcutaneous Cell-Line-Derived Xenograft
- Breast Cancer Modeling
- Orthotopic Cell-Line Xenograft
Product Details
Chemical Information
-
CAS No. 3028851-79-5
-
SMILES
N/A
-
Synonyms
OMTX005+TAM470
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- OMTX 705
- 3028851-79-5
- OMTX005+TAM470
- OMTX705
- OMTX-705
- Antibody-Drug Conjugates (ADCs)
- FAP
- Caspase
- Apoptosis
- Antibody-Drug Conjugates
- ADC
- Fibroblast activation protein
- CD8+ cytotoxic T cells
- PDX models
- apoptosis
- cancer-associated fibroblasts
- caspase 3/7
- late endosomes
- pancreatic cancer
- solid tumors
- tumor stroma
- Inhibitor
- inhibitor
- inhibit